Ryboquin Raises £1.3m for Cancer Drug Development

A Scottish Borders-based pharmaceutical firm, Ryboquin has raised £1.3m towards cancer gene therapy drug development. The money will allow Ryboquin Ltd to take the product – named Ryboquin ECP-102 – one step closer to clinical trials. The firm, which has its headquarters in Selkirk, raised £800,000 from investors plus nearly £500,000 in a Scottish Enterprise

Continue Reading

Pfizer to Test Cancer Immunotherapy Combination

Pfizer is reportedly gearing up to test a combination of three cancer drugs in human trials next year. According to the Financial Times, the trial, which will be one of the first to test a trio of immunotherapies, will monitor the safety and efficacy of the combination in patients with solid cancers. Although current immunotherapies

Continue Reading

Three New Drugs Approved for Use on NHS Scotland

Three new medicines have been granted approval by cost regulators for use on NHS Scotland. The new treatments will offer options to patients for breast cancer, prostate cancer and heart failure. The Scottish Medicines Consortium has now accepted use of Eisai’s Halaven (eribulin) for the treatment of advanced breast cancer in those patients who have

Continue Reading

Three New Drugs Green-Lighted for NHS Scotland

Cost regulators for the NHS in Scotland have endorsed new medicines for the treatment of HIV, asthma and MRSA-related skin infections. The SMC (Scottish Medicines Consortium) put forward Janssen-Cilag’s Rezolsta (darunavir cobicistat) in combination with another antiretroviral as an option for the treatment of HIV-1 infection in adults aged 18 years or older. Rezolsta combines

Continue Reading

Cancer Research Technology, the Institute of Cancer Research and Janssen Partner for Myeloma Drug

Cancer Research Technology (CRT) and the Institute of Cancer Research (ICR) announced earlier today that they have partnered with Johnson & Johnson unit, Janssen Biotech, in an agreement to discover a potential new drug for the blood cancer, multiple myeloma. The partnership is aiming to identify molecules and develop them into experimental therapies that block

Continue Reading